Canadian panel says Vioxx is safe enough to return to market

Share this article:

By a vote of 12 to 1, a panel of Canadian health advisors said Thursday that Merck's COX-2 drug Vioxx should be allowed to go on sale again in the country.
The panel said the risk of heart disease from Vioxx was the same as posed by similar painkillers and that gastrointestinal effect appeared to be less.
The panel met last month to discuss the risks of Vioxx and Pfizer's Bextra and Celebrex.
The group of advisors was unanimous in recommending Celebrex be allowed to remain on the market but voted against reintroducing Bextra because of its risk of a rare but serious skin disorder.
A Merck spokesperson told Reuters on Thursday the company has not decided whether to put Vioxx back on the market in Canada or anywhere else.

 

 

 

 

 

Share this article:

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.